Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epratuzumab Y-90

Drug Profile

Epratuzumab Y-90

Alternative Names: 90Y-DOTA-hLL2; 90Y-Epratuzumab; 90Y-hLL2; 90Y-hLL2 IgG; Anti-CD22 monoclonal antibody LL2-Y-90; hCD22-Y-90; IMMU-102; Monoclonal antibody LL2-Y-90; Y-90 epratuzumab tetraxetan; Yttrium-90 epratuzumab tetraxetan; Yttrium-90-labelled epratuzumab

Latest Information Update: 13 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Developer Immunomedics; Nantes University Hospital; Weill Cornell Medical College
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Follicular lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Diffuse large B cell lymphoma

Most Recent Events

  • 01 Apr 2017 Immunomedics terminates a phase I/II trial due to slow patient accrual in Follicular lymphoma (Combination therapy, First-line therapy) in USA (IV) (NCT01147393)
  • 17 Jan 2017 Nantes University Hospital withdraws the phase I/II EPRALLO trial prior to enrolment for Acute lymphoblastic leukaemia in France (NCT02577094)
  • 26 Oct 2015 Nantes University Hospital plans the phase I/II EPRALLO trial for Acute lymphoblastic leukaemia in France (NCT02577094)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top